Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER’S DISEASE

A needle for Alzheimer’s in a haystack of claims data

An Author Correction to this article was published on 11 January 2022

This article has been updated

In the era of big data, looking for insights in large datasets has become the norm — and health data are no exception. Combining systems-biology-driven, endophenotype-based analysis of drug targets with large-scale medical claims data points to sildenafil as a potential treatment opportunity for Alzheimer’s disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Endophenotype-based drug prioritization and population-based validation for drug repurposing in Alzheimer’s disease.

Change history

References

  1. Fang, J. et al. Nat. Aging https://doi.org/10.1038/s43587-021-00138-z (2021).

  2. Uthayathas, S. et al. Pharmacol. Rep. PR 59, 150–163 (2007).

    CAS  PubMed  Google Scholar 

  3. Sanders, O. J. Alzheimers Dis. Rep. 4, 91–106 (2020).

    Article  Google Scholar 

  4. Gottesman, I. I. & Gould, T. D. Am. J. Psychiatry 160, 636–645 (2003).

    Article  Google Scholar 

  5. Guney, E., Menche, J., Vidal, M. & Barábasi, A.-L. Nat. Commun. 7, 10331 (2016).

    Article  CAS  Google Scholar 

  6. Ghiassian, S. D. et al. Sci. Rep. 6, 27414 (2016).

    Article  CAS  Google Scholar 

  7. Menche, J. et al. Science 347, 1257601 (2015).

    Article  Google Scholar 

  8. Aguirre-Plans, J. et al. Pharmaceuticals 11, 61 (2018).

    Article  CAS  Google Scholar 

  9. Cheng, F. et al. Nat. Commun. 9, 2691 (2018).

    Article  Google Scholar 

  10. Langhauser, F. et al. NPJ Syst. Biol. Appl. 4, 8 (2018).

    Article  Google Scholar 

  11. Aguirre-Plans, J. et al. J. Mol. Biol. 431, 2477–2484 (2019).

    Article  CAS  Google Scholar 

  12. Cirillo, D. et al. NPJ Digit. Med. 3, 81 (2020).

    Article  Google Scholar 

  13. Bearden, C. E. & Freimer, N. B. Trends Genet. 22, 306–313 (2006).

    Article  CAS  Google Scholar 

  14. Geifman, N., Kennedy, R. E., Schneider, L. S., Buchan, I. & Brinton, R. D. Alzheimers Res. Ther. 10, 4 (2018).

    Article  Google Scholar 

  15. Götz, J., Matamales, M., Götz, N. N., Ittner, L. M. & Eckert, A. Front. Physiol. 3, 320 (2012).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emre Guney.

Ethics declarations

Competing interests

E.G. is an employee of STALICLA, a clinical-stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders through endophenotyping and artificial intelligence. A.A. is an employee of Accenture.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guney, E., Athie, A. A needle for Alzheimer’s in a haystack of claims data. Nat Aging 1, 1083–1085 (2021). https://doi.org/10.1038/s43587-021-00139-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-021-00139-y

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing